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Abstract
From 1999 to 2014, over 165,000 persons in the United States died from an overdose related to
prescription opioids (Centers for Disease Control and Prevention [CDC], 2016). In response, the
CDC released guidelines that propose nonpharmacologic and nonopioid pharmacologic therapy
as preferred methods for chronic pain control (Dowell et al., 2016). The purpose of this project
was to examine the biopsychosocial multidisciplinary treatment impact on risk of opioid
medication misuse among adult chronic opioid-dependent noncancer pain clinic patients with
and without a psychiatric disorder. Engel’s (1977) biopsychosocial model was used to evaluate
whether multidisciplinary treatment impacted the risk of opioid misuse for noncancer chronic
pain patients at San Diego Pain Institute pain management clinic. A quantitative retrospective
four-group design study was completed to determine whether biopsychosocial multidisciplinary
treatment impacts the risk of opioid medication misuse. A medical chart review was used to
identify those patients with and without a psychiatric disorder who are participating in a
biopsychosocial treatment program comprising (a) a pain management program, (b) a physical
therapy program, and (c) cognitive behavioral therapy (CBT) and those who are not participating
in a treatment program with those three services. The Pain Medication Questionnaire (PMQ) was
used to compare the risk of opioid medication misuse between the four groups (Adams et al.,
2004). The results showed a biopsychosocial multidisciplinary treatment approach comprising
pain management, physical therapy, and CBT reduced the risk of opioid medication misuse
among chronic pain patients with a psychiatric disorder and may provide patients and providers
an alternative method for opioid misuse prevention.
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Chapter 1. Introduction and Background
In 1980, a letter published in the New England Journal of Medicine reported that only 4
out of 11,882 hospitalized people prescribed opioids became addicted (Porter & Jick, 1980). Six
years later, Portenoy and Foley (1986) evaluated 38 patients to determine the indications, course,
safety, and efficacy of opioid analgesics for nonmalignant pain and concluded that opioid
maintenance therapy was a safe and effective alternative for intractable nonmalignant pain. In
1996, the American Pain Society introduced pain as the “5th vital sign,” and this concept was
also adopted by the Veterans Health Administration (Levy et al., 2018). That same year, the
American Academy of Pain Medicine and the American Pain Society determined that opioids
should be included as a treatment option for chronic noncancer pain. Subsequently, the Food and
Drug Administration approved the manufacturing of OxyContin, a long-acting opioid, by Purdue
Pharmaceuticals (Hirsch, 2017). In 2001, the Joint Commission on Accreditation of Healthcare
Organizations standardized the use of the pain scale, which resulted in a combination of
published medical studies and pharmaceutical influence contributing to opioid prescribing as an
accepted method in reducing the numerical value of pain (Hirsch, 2017). As opioid prescribing
increased, the risks associated with chronic prescription opioid use became increasingly evident
among adults in the United States. From 1999 to 2014 in the United States, over 165,000 persons
died from an overdose related to prescription opioids (CDC, 2016). Furthermore, extant research
lends little support to the effectiveness of long-term opioid therapy to treat chronic pain
(Buchman et al., 2016). In 2007, an affiliate of Purdue Pharma and three Purdue Pharma
executives pled guilty to criminal charges related to misleading the public regarding the
addictive properties of OxyContin. The case was subsequently settled with a $634.5 million fine
(Zee, 2009).
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The estimated cost of addressing the impact of substance abuse in the United States is
more than $600 billion annually (Substance Abuse and Mental Health Services Administration
[SAMHSA], 2019b). According to the 2018 National Survey on Drug Use and Health, an
estimated 2 million people aged 12 or older had an opioid use disorder (SAMHSA, 2019a).
Despite the lack of evidence supporting continuous opioid use for chronic pain, opioid therapy is
the most prescribed treatment for chronic pain (Speed et al., 2018). Unfortunately, prescription
opioid use can lead to opioid use disorder, which is common among individuals with chronic
pain. Using an electronic health record database, Hser et al. (2017) examined chronic pain in
5,307 adult patients with opioid use disorder. The study compared the presence of comorbidities,
such as substance use disorder, mental health disorders, and disease conditions. Importantly,
64.4% of opioid use disorder patients had chronic pain, and 61.8% of those had chronic pain
before opioid use disorder. Moreover, opioid use disorder is associated with increased morbidity
and mortality (Hser et al., 2018).
In 2015, the Medical Board of California initiated the Death Certificate Project, in which
investigators review the Department of Justice’s prescription drug database to identify opioid
prescribers. These results are then cross-referenced to patients who died from an opioid overdose
(Dembosky, 2019). Once the opioid prescriber has been identified, an investigation is launched
to review their practices. The project has been criticized because it includes any prescriber who
provided opioids three years before the patient’s death; does not account for suicide by overdose;
and reviews records as far back as 2013, which is three years before the CDC opioid guidelines
were issued.
In 2016, the CDC released guidelines for opioid prescribing that proposed
nonpharmacologic and nonopioid pharmacologic therapy as preferred methods for treating
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chronic pain, with the goal of altering clinicians’ prescribing habits (Dowell et al., 2016). The
opioid guidelines were developed using the Grading of Recommendations Assessment,
Development, and Evaluation method, which is a framework for presenting summaries of
evidence, appraising controlled studies, and applying a systematic approach for clinical practice
recommendations. The guidelines are intended for those 18 years or older with chronic pain
(defined as pain lasting more than 3 months) outside of palliative and end-of-life care. Nonopioid
options, such as physical therapy, clinical pain psychology, acupuncture, and nonsteroidal antiinflammatories, are recommended as a first line of therapy. After opioid therapy has been
initiated, the recommendation is to reassess the benefits and risks of opioid therapy when
increasing the dosage to 50 or more morphine milligram equivalents (MME) per day and to
avoid increasing the dose to 90 or more MME/day. While the CDC recommends nonopioid
medications as a first-line therapy, it acknowledges that many people suffer from side effects
associated with those medications. The CDC also acknowledges that pain is subjective and
dependent on individual needs, which can lead to doses greater than 90 MME/day (Dowell et al.,
2016). Conservative therapies, such as clinical pain psychology, physical therapy, and
acupuncture, are recommended; however, some insurance plans may not provide coverage for
this therapy, and the out-of-pocket costs can be high. The CDC (2016) also recognizes that
limitations in complex activities; lost work productivity; reduced quality of life; stigmas; and
biological, psychological, and social factors are associated with chronic pain. Multidisciplinary
therapies that address biological, psychological, and social factors associated with chronic pain
have been shown to reduce pain and improve functionality more effectively when compared to
single-focus therapies (Miller-Matero et al., 2016).
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Problem Statement
In 2017, the U.S. Department of Health and Human Services (2019) declared an opioid
crisis and identified an increase in the rate of opioid prescriptions as a contributing factor
(Volkow & Blanco, 2021). With the declaration of an opioid crisis, introduction of the CDC
opioid prescribing guidelines, and the creation of the Death Certificate Project, methods to
prevent opioid misuse must be identified. Current research has emphasized the dangers
associated with prescription opioids and the benefits of multidisciplinary treatment (Craner et al.,
2016; Huhn et al., 2019; Kamper et al., 2015; Purcell et al., 2019). However, few studies have
been conducted exploring how biopsychosocial treatment affects opioid use (Dowell et al.,
2016). The purpose of this project was to examine the association between biopsychosocial
multidisciplinary treatment and the risk of opioid medication misuse among adult chronic opioiddependent noncancer pain clinic patients.
PICOT Question
For (P) chronic pain patients with and without a psychiatric disorder, as defined by the
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (I) does biopsychosocial
multidisciplinary treatment positively impact the risk of opioid medication misuse, (C) compared
to no biopsychosocial multidisciplinary treatment, (O) as observed by a lower score on the Pain
Medication Questionnaire?
Objectives and Aims
The objective of this study was to determine the effectiveness of biopsychosocial
multidisciplinary treatment as an alternative method for pain management in order to prevent
opioid misuse. This study aimed to evaluate the risk of opioid medication misuse among
noncancer chronic pain patients actively in biopsychosocial multidisciplinary treatment,
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compared to those who are not, at the San Diego Pain Institute outpatient pain management
clinic.
Chapter 2. Literature Review
To explore the concept of biopsychosocial multidisciplinary treatment and opioid misuse,
the researcher conducted an electronic database literature search using Worldcat.org, PubMed,
ScienceDirect, Cochrane Library, BioMed Central, and Google Scholar and the terms
“biopsychosocial model chronic pain” and “biopsychosocial model opioids.” Inclusion criteria
consisted of English-language, peer-reviewed, full-text articles published within the past five
years. Pediatric and opinionated articles were excluded. Article screening resulted in the
selection of five studies that correlated the biopsychosocial model, pain reduction, and opioid
use.
Integration of the Biopsychosocial Model Among Veterans
Purcell et al. (2019) explored the idea of whether biopsychosocial model integration can
improve the care experience among Department of Veterans Affairs (VA) chronic pain patients.
They designed a qualitative study to evaluate 41 patients treated by an integrated pain team (i.e.,
medical provider, psychologist, and pharmacist) in the primary care setting. The integrated pain
team prescribed opioid medication; educated the patients about chronic pain; and provided
behavioral interventions, psychotherapy, and self-management strategies for pain reduction.
They conducted telephonic semistructured interviews with those who had completed at least
three visits with the integrated pain team at the San Francisco VA. Exclusion criteria included
untreated mental illness and active suicidal or homicidal thoughts. Interview times ranged from
30 to 60 minutes, with a response rate of 49%. Questions focused on the overall experience,
impact of pain care, quality of life, and pros and cons of working with the integrated pain team.
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Results of the study were categorized into three themes: (a) interdisciplinary treatment
model, (b) treatment planning and communication, and (c) treatment results and impact. Patient
experiences with the interdisciplinary treatment model were described as both effective and
beneficial by some patients but awkward and confusing by others. Treatment planning and
communication produced conflicting results because some patients viewed their individuality as
being appreciated, whereas others viewed opioid reduction as being the primary goal of the
integrated pain team’s treatment plan, regardless of pain levels. Regarding treatment results and
impact, nearly all patients underwent opioid reduction or elimination. This opioid reduction led
to improved pain control, quality of life, and functionality for some patients; however, those
issues worsened for others. Rigor, validity, and credibility of the study were achieved through
intercoder agreement of central themes; analyst triangulation of interviews; robust sample size;
and the use of rich, thick descriptions. Limitations included selection bias and potential inability
to generalize findings to nonveteran or veteran patients at other VA facilities.
Associations of Multiple Sclerosis Pain
Day et al. (2016) conducted a quantitative cross-sectional survey among adults ages 21 to
81 years with multiple sclerosis (MS) to (a) identify associations between pain, MS symptoms,
depression, and psychosocial and functional variables and (b) determine whether MS duration,
subtype, and demographics function as risks and protective factors among pain, MS symptoms,
depression, and psychosocial and functional variables. A sample of 424 (92% White and 80%
female) participants were recruited by mailed letter invitation from the Greater Northwest
Washington chapter of the National Multiple Sclerosis Society. Interested individuals were
provided a mailed or online link to the survey. Surveys with missing data were followed up by
phone, and all participants received a $25 gift card upon completion. The survey consisted of a
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demographic questionnaire and self-reported measures to assess pain severity, pain interference,
depression, fatigue, and insomnia. Statistical data analysis to explore the variables’ associations
was completed with Mplus version 7.2.
The results supported two primary themes: (a) the functional variables of pain
interference, sleep quality, and fatigue were not correlated after controlling for MS symptoms,
depression, and pain severity, and (b) underlying symptoms, such as pain, fatigue, depression,
and sleep impairment, should be evaluated and managed in those with MS. A secondary result
found that those with depression, low socioeconomic status, or lack of social support may be at
risk for poor outcomes in pain and MS. These findings suggest that pain and MS symptoms
could improve with coping skills and social support interventions. Limitations included the
study’s narrow demographic profile, which prevents generalization; reliance on self-report
measures, which may limit accuracy; and the short time frame. Longitudinal studies may provide
more accurate information because depression, sleep disturbance, and fatigue may manifest
physical symptoms that are undetectable in short-term studies.
Meta-analysis of Multidisciplinary Treatment
Kamper et al. (2015) completed a systematic review and random effects meta-analysis of
41 randomized controlled trials to assess the effectiveness of multidisciplinary rehabilitation in
pain reduction, disability, and work absence in adult patients with chronic (lasting more than 3
months) low back pain. Multidisciplinary rehabilitation comprised biopsychosocial concepts and
was defined as physical, psychological, social, and work interventions. Inclusion criteria were
any language, full-text, and peer-reviewed journals.
Seventy-five percent of reported patients had chronic low back pain, and 25% of reported
patients had low back pain. Specific causative factors of low back pain, such as metastasis or
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infection, were excluded from the study. Multidisciplinary rehabilitation was compared to the
control interventions of usual care, physical treatment, surgery, and waiting list. Pain, disability,
and work absenteeism were identified as long-term (12-month or longer assessments) primary
outcomes. Psychological functioning, quality of life, adverse events, and health service
utilization were identified as short-term (less than 12-month assessments) secondary outcomes.
The researchers searched the Cochrane Back Review Group Trials Register, CENTRAL,
MEDLINE, Embase, PsycINFO, and CINAHL databases for articles published between 1998
and February 2014. They then assessed the quality of the collected evidence with the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) approach and the bias
risk with the 12-point Cochrane Risk of Bias Tool. To conduct the statistical analysis, they used
the RevMan 5.1 software. The findings of the statistical analysis revealed that multidisciplinary
rehabilitation interventions were significantly more effective in pain reduction and disability
compared to usual care and physical treatment and that, secondarily, they seemed to be more
effective for work outcomes compared to physical treatment. Kamper et al. (2015) concluded
that multidisciplinary rehabilitation using biopsychosocial concepts can reduce pain. Limitations
of the study included inconsistent measurements of work absenteeism, diverse definition of
physical treatments, and inability to generalize findings because most studies occurred in Europe.
Perspectives of Chronic Pain Patients
To understand the perspectives of chronic pain patients, Craner et al. (2016) conducted a
mixed methods study to investigate what patients perceive as important for pain management.
The study consisted of a 120-hour group-based outpatient pain rehabilitation program
comprising cognitive behavioral and biopsychosocial concepts of chronic pain treatment. The
study’s pain rehabilitation program incorporated multiple modalities, such as CBT, physical
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therapy, biofeedback, family education, occupational therapy, pharmaceutical education, and
relaxation training. Patients completed the West Haven-Yale Multidimensional Pain Inventory
before and after the program. Four hundred ninety-eight out of 679 chronic pain patients ages 18
years and older completed the study. At admission, 14.7% of patients were considering
additional surgery for pain alleviation, and 22.9% were unsure. The researchers obtained patient
demographics through reviewing medical records and collected computerized assessment
measures upon admission and discharge. They then completed the statistical analysis using the
IBM SPSS Statistics version 22.0 software.
Upon program completion, 88.7% of the patients had discontinued opioid use, 6.1% of
the patients who had considered additional surgery were no longer considering it, 16% of the
patients who were unsure whether they would have additional surgery no longer considered
surgery an option, and pain severity and pain interference had each decreased by 1.3 points.
Relaxation strategies were the most endorsed (84.7%) by patients, with 82.7% referencing
diaphragmatic breathing techniques. Activity modification was endorsed by 47.4% of patients,
24.3% of patients endorsed positive self-talk, and 16.2% of patients endorsed distraction
techniques. The results of the study indicated that relaxation strategies were the most useful tool
for pain reduction. Opioid medication use also declined, despite not being the study’s primary
goal.
Associations of Chronic Pelvic Pain
Miller-Matero et al. (2016) examined the associations of pain, psychological symptoms,
and functional impairment among chronic pelvic pain patients. They conducted a retrospective
chart review to evaluate 107 female patients between the ages of 18 and 67 who were evaluated
by a physician at a multidisciplinary chronic pelvic pain clinic. The researchers then used a
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convenience sample to review the records of those who had completed a routine psychiatric
evaluation and the Hospital Anxiety and Depression Scale (HADS), which is a 14-item selfreport questionnaire designed to evaluate the symptoms of depression and anxiety. The routine
psychiatric evaluation consisted of a semistructured interview regarding history of pelvic pain,
psychosocial factors (e.g., history of psychiatric symptoms and emotional and sexual abuse),
existing functional impairments, and completing the visual analog pain scale questionnaire. They
conducted the statistical analysis with SPSS version 20.
The study results indicated that 53.8% of patients had had a history of a depressive
episode; 25.7% endorsed experiencing current probable depression; 38.6% endorsed
experiencing current probable anxiety; and 44.9% had experienced some form of abuse, with the
majority (72.7%) being sexually abused. Chronic pelvic pain was present in 8.9% for less than 6
months, 7.8% for 6 to 12 months, 34.4% for 1 to 5 years, 15.6% for 5 to 10 years, and 33.3%
longer than 10 years. Functional impairment of household activities was present in 66.4% of
patients, followed by sleep deficits in 53.3%. A comparison of those with and without
impairment in household activities, t(106) = −2.06, p = .04, and sleep, t(106) = −2.61, p = .01,
indicated a significant correlation with higher levels of anxiety. A comparison of those with and
without impairment in household activities, t(106) = −3.72, p = <.001, and sleep, t(106) = −2.40,
p = .02, indicated a significant correlation with higher levels of depression. Pain severity was not
significantly associated with anxiety, r(106) = .13, p = .24, or depression, r(106) = .08, p = .44.
A comparison of pain severity scores between those with and without a history of emotional and
sexual abuse found no statistical difference, t(106) = −.26, p = .80. The findings suggested that
impairments are associated with depression and anxiety, not pain severity. Based on the results,
Miller-Matero et al. (2016) determined that a multifaceted approach incorporating both medical
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and psychological therapies may be beneficial in the evaluation and treatment of chronic pelvic
pain. Limitations included the study’s narrow demographic profile of chronic pelvic pain
patients; reliance on self-report measures, which may limit accuracy; and limited research
indicating the effectiveness of psychological treatments for chronic pelvic pain patients.
Discussion
The literature review provided relevant data regarding the associated factors of pain;
however, the studies are not without their limitations. Miller-Matero et al. (2016) evaluated
females only; therefore, the results cannot be generalized to both sexes. It should also be noted
that Kamper et al.’s (2015) study identified chronic pain as pain lasting more than 3 months,
whereas the other studies lacked a definition, and that the study did include articles in which at
least 75% of the participants had chronic low back pain and 25% did not; those 25% may have
skewed the results. The limitations of the Craner et al. (2016) study included lack of diversity
(95% Caucasian); high education level of participants (mean of 14.9 years); and peer influences,
all of which could affect generalization. Miller-Matero et al. (2016) relied on self-reports, rather
than objective data, which could have potentially affected the results.
While it is promising that all studies reported pain reduction, the reduction of opioid use
that was noted in Purcell et al.’s (2019) study should be further explored because some patients
reported increased pain. Perhaps reports of increased pain represented the patient’s mistrust of
the integrated pain team. Some patients viewed opioid reduction as the treatment’s primary goal
regardless of pain levels. Therefore, the study emphasized the importance of discussing that the
goal of the biopsychosocial model is to improve pain management, not opioid reduction. Day et
al.’s (2016) highlighting of increased risk for poor outcomes in pain among those with low
socioeconomic status and lack of social support leads to the question of whether those with good
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socioeconomical standing would benefit from a biopsychosocial model. If true, limited resources
may present a challenge in biopsychosocial model implementation among those with low
socioeconomic status because it can be costly and time consuming (Cheatle, 2016). Craner et
al.’s (2016) qualitative coding methods were not directly specified, which could have affected
the reliability and validity of their study.
The qualitative study by Purcell et al. (2019) noted that all patients underwent an opioid
reduction or elimination while undergoing multidisciplinary treatment. Day et al.’s (2016)
quantitative cross-sectional survey method used a self-assessment tool to evaluate the
associations of pain, functionality, and psychological variants, the results of which suggested
pain symptoms could improve with coping skills and social support interventions. These findings
correlate with the findings of Kamper et al.’s (2015) systematic review, where it was also
concluded that multidisciplinary rehabilitation using biopsychosocial concepts can reduce pain.
Despite not being the primary goal, pain reduction was also noted in the study by Craner et al.
(2016). These findings are consistent with the study by Day et al. (2016), who also found that a
biopsychosocial program led to pain reduction. The study by Miller-Matero et al. (2016) found
that psychological symptoms, not pain, were associated with functional impairment in patients
with chronic pelvic pain, and they concluded that incorporating both medical and psychological
therapies may be beneficial in its treatment.
Historically, opioid prescribing has been an accepted method for pain reduction. The
results of these studies present an understanding that the concept of pain encompasses biological,
psychological, and social factors and is not just a numerical value. It is apparent to prescribers
that the reliance on pain scales to determine severity of pain can result in unnecessary opioid
prescribing to reduce the experience of pain (Speed et al., 2018). The risk for misuse of
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prescribed opioids is much higher in patients with chronic pain (Hser et al., 2017). Currently,
therapeutic approaches are needed that balance treating chronic pain and minimizing risks for
opioid misuse. The CDC (2016) recommends opioid misuse monitoring strategies, such as the
use of risk assessment instruments, opioid management plans, patient education, prescription
drug monitoring program data, pill counts, and urine drug testing. However, the CDC (2016)
recognizes that research is unavailable that demonstrates the effectiveness of those strategies.
The researchers of the reviewed articles concluded that implementation of a biopsychosocial
multidisciplinary team approach for pain management resulted in pain reduction. Once
appropriate pain relief had been established, opioid misuse behaviors tended to decrease (Kaye et
al., 2017). The researcher anticipated that those who are actively being treated with a
biopsychosocial multidisciplinary team approach will have a decreased risk of opioid misuse.
Chapter 3. Theoretical Model and Methodology
Theoretical Model
Engel’s (1977) biopsychosocial model provides a systematic interdisciplinary approach
to health and wellness. The model considers biological, psychological, and social factors as
equivalent and interrelated components in health and wellness (Figure 1). Modification of any
component can directly or indirectly influence the other components. Published research using
this model continues to grow because it is frequently used in rehabilitation, disability, and
chronic pain research and is one of the most recognizable and best-established models (Wade &
Halligan, 2017).
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Figure 1
Biopsychosocial Model

Biological

Psychological

Health and Wellness

Social

The biological component of the model accounts for physiological causes, clinical data,
pathological issues, and disabilities. The contributions of the biological component in chronic
pain are evident in the study by Huhn et al. (2019), who used the Brief Pain Inventory, Pain
Catastrophizing Scale, and Subjective Opioid Withdrawal Scale to survey 101 men and 80
women to assess the relationship between pain and opioid misuse. The results indicated that
women reported higher levels of current, average, and worst pain compared to men. A clinician’s
role is to recognize these biological factors and devise a treatment plan to manage chronic pain
and improve functionality. The addition of rehabilitative services, such as physical therapy, to
address physiological causes for chronic pain has been shown to reduce opioid use (Sun et al.,
2018).
The psychological component of the model accounts for human experiences, behavior,
personality, and underlying mental health conditions as influential factors. This relationship is
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evident in those with anxiety and chronic pain. Rogers et al. (2020) completed a cross-sectional
analysis of 396 adults with chronic pain and found that pain-related anxiety significantly
mediated the relationship between pain severity, opioid misuse outcomes, and psychosocial
disability. CBT is a form of personalized psychological therapy that provides learning strategies
to explore one’s thought processes and how they connect concepts. CBT can assist in revealing
negative thinking and provide tools to address challenges in an effective way, evaluate family
and social dynamics, and provide patient and family education (Majeed & Sudak, 2017). CBT
has also been shown to reduce opioid medication misuse (Wilson et al., 2015).
The social component of the model accounts for community, environment, religion,
culture, peers, family, and economic background. The concept of pain is known to be influenced
by cultural and social factors. Some religions view pain as a necessity to bringing one closer to
God. Seen in this light, as a positive process, pain would be accepted by sufferers as a challenge
to deepen their religious faith (D’emeh et al., 2016).
The concept of pain is a subjective experience unique to each person. Relying on the use
of opioid medications for chronic pain management has led to an opioid crisis. Liberal opioid
prescribing practices have also led to health provider license suspensions. The biopsychosocial
model recognizes that physical, psychological, and social factors are related, and it promotes an
integrated approach to treatment. The incorporation of clinical pain management, physical
therapy, and CBT to address those factors in chronic pain patients should reduce the risk of
opioid medication misuse.
Project and Study Design
The researcher used a quantitative retrospective four-group study design and conducted a
medical chart review to identify patients with and without a psychiatric disorder diagnosis who
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were participating in a biopsychosocial treatment program comprising (a) a pain management
program, (b) a physical therapy program, and (c) CBT and those who were not participating in a
program with those three services. The Pain Medication Questionnaire (PMQ; Appendix A) was
provided to the four groups, who were allotted 14 days in which to complete and return it via the
provided prepaid postage envelope. Participants were contacted on day 15 via text or telephone if
responses had not yet been received. The study design was compatible with what this study was
seeking—data collection at a single point in time with a four-group comparison.
Setting and Resources
The study was conducted at the San Diego Pain Institute outpatient pain management
clinic. For two years, the researcher collaborated with the management group at San Diego Pain
Institute in San Diego, California, regarding the association between biopsychosocial
multidisciplinary treatment and its impact on risk of opioid medication misuse. Support was
obtained from San Diego Pain Institute after the researcher presented evidence indicating
biopsychosocial multidisciplinary treatment may impact the risk of opioid misuse among chronic
pain patients (Kamper et al., 2015). The managers and ancillary staff agreed to no direct
involvement with the study except for one clinical staff member employed by San Diego Pain
Institute who assisted in data collection. Office equipment, printing materials, Amazon gift cards,
and REDCap software were used.
Study Population
Participants were recruited into the study by the clinical staff member at San Diego Pain
Institute outpatient pain management clinic. The clinical staff member performed a retrospective
chart review of 435 medical charts, dated from July 19, 2020, through November 2, 2020. Power
analysis was conducted with G*Power 3.1 to calculate a one-way analysis of variance (ANOVA)
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sample size. A total sample size of 180 was calculated using input parameters of medium effect
size of 0.25 (Cohen’s f), error probability of 0.05, power of 0.80, and number of groups of 4. A
convenience sample of 435 participants were identified in the chart review to ensure the target
sample size of 180 was obtained. The total sample size was evenly distributed among four
groups of 45 each. The sampling frame consisted of patients from San Diego Pain Institute
outpatient pain management clinic who were and were not actively being treated with pain
management, physical therapy, and CBT.
Inclusion Criteria
Following are the inclusion criteria:
•

Diagnosed with chronic pain (pain > 6 months)

•

Age ≥ 18 years

•

No active pregnancy

•

English speaking

•

No history of substance abuse

•

Not actively using medical cannabis and/or illegal substances

•

Treated with continuous opioid therapy > 6 months

•

Morphine equivalence > 50 MME/day

•

No presence of terminal illness

•

Not a surgical candidate

•

Actively being treated by pain management

•

Physical therapy and CBT for 3 consecutive months

•

Actively being treated by pain management only

•

Actively being treated by pain management and physical therapy only
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Actively being treated by pain management and CBT only

Exclusion Criteria
Following are the exclusion criteria:
•

Pain present for < 6 months

•

Actively incarcerated

•

History of substance abuse

•

Actively using medical cannabis and/or illegal substances

•

Has not tried and failed conservative therapy

•

Surgical candidate

•

Treated with continuous opioid therapy < 6 months

•

Morphine equivalence < 50 MME/day

Sources of Data
The PMQ was used to measure risk of opioid medication misuse (Adams et al., 2004).
This self-assessment instrument was designed to assess for the risk of medication misuse among
chronic pain patients through a 26-item questionnaire that measures dysfunctional attitudes and
aberrant behaviors associated with the use of pain medication (Adams et al., 2004). Items include
1. I have clear preferences about the type of pain medication I need; 2. My pain medication
makes it hard for me to think clearly sometimes; and 3. At times, I think I may be too dependent
on my pain medication. The PMQ is a 5-point Likert scale with each point representing a verbal
anchor to reflect a person’s conformity with a behavior (Adams et al., 2004). Reponses range
from 0 (never) to 4 (always). Pearson’s r is .85, and Cronbach’s alpha is .73 (Adams et al.,
2004). Higher scores (70 to 104) are associated with reduced functionality, substance abuse
history, and increased levels of psychosocial distress. Lower scores (0 to 34) are associated with
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a lower risk group and lower potential for opioid misuse (Adams et al., 2004). Higher scores
reflect greater presence of behaviors associated with potential risk for opioid misuse.
The researcher provided each patient with a PMQ, which was collected after 2 weeks.
Those who did not complete the PMQ within 2 weeks were reminded via telephone or text by the
clinical staff member and provided one additional week. A $5 Amazon gift card was given to
those who completed the study in its entirety. Demographic data of sex, age, educational level,
and daily MME were collected via chart review. Daily MME was calculated with the formula
strength per unit × (number of units/day supply) × MME conversion factor = MME/day (CDC,
2016). Names and addresses were redacted, and the PMQ results were accessible only to the
researcher.
Data Analysis
Survey responses and opioid doses were examined with descriptive statistics (median,
mean, and standard deviation), histograms, Q-Q plots, and boxplots. The normality, linearity,
and equal variance assumptions were met. The differences in responses in the four groups were
assessed with a one-way ANOVA. Significance was set at a p-value of ≤0.05. Statistical analysis
was completed with IBM SPSS Statistics version 27 software.
Quality
Internal Validity—Maturation
Summertime was avoided due to the high probability of vacations. Severe winter weather
was avoided due to the possibility of higher-than-normal pain levels. The PMQ was found to be
highly reliable (26 items; α = .88).
Construct Validity—Experimenter Expectancies
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Because the investigator may influence the participants’ questionnaire responses, the
researcher did not directly interact with the participants during the questionnaire. All participants
had the same standardized process to access and complete the PMQ.
Statistical Conclusion Validity—Low Statistical Power
To increase the sample size, a $5 Amazon gift card was provided as an incentive to
complete the PMQ. Sample size was calculated using a medium effect size of 0.25 (Cohen’s f)
and a power of 0.80.
Ethics and Human Subjects Protection
Confidentiality
Dates of birth and geographic identifiers, such as address, zip code, city, and county,
were not collected. The clinical staff member conducted the retrospective medical chart review.
Competence
The researcher, Michael Palacio, is a board-certified nurse practitioner who has actively
practiced in pain management for over 9 years. He provides pain management education for over
4,000 patients annually, trains health care providers in pain management, provides legal expert
witness testimony for health-related cases, and is an expert practice consultant for the California
Board of Nursing. He has authored evidenced-based institutional policies for University of New
Mexico Hospital, New Mexico Pain and Spine, and San Diego Pain Institute.
Institutional Approval
The University of New Mexico Health Sciences Institutional Review Board (IRB)
obtained approval for the research protocol before the process was begun. Participants were
informed and educated about the research and provided voluntary informed consent before they
participated in the study. Participants were free to withdraw at any time and instructed to contact
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the IRB with any concerns they may have had about the study. Potential benefits for participants
included contribution to health care advancements, compensation, and knowledge gain. Potential
harms included severe emotional strain and unintentional disclosure of private data.
Reimbursement for two counseling sessions up to $150 and reimbursement of identity theft
protection up to $120 were offered to those who experienced adverse effects.
Time Frame
8/3/20: Met with key stakeholders individually to review study and answer any
remaining questions
8/5/20: Drafted informed consent letter
8/7/20: Submitted IRB application
10/1/20: Obtained IRB approval
10/2/20: Placed posters in clinic regarding study and began recruitment
10/3/20: Began retrospective chart review
11/2/20: Analyzed chart review results
11/9/20: Provided PMQ access to participants
11/15/20: Began providing $5 Amazon gift cards to participants
11/23/20: Collected PMQ responses, and clinical staff member contacted those who did
not complete the questionnaire
3/2/21: Collected remaining PMQ responses
3/2/21: Began analysis of PMQ responses
3/6/21: Completed analysis of all data
3/7/21: Reviewed results and began final write-up
4/17/20: Completed final write-up
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Total time: 8.5 months
Operational Budget
Office and printing supplies: $60
Amazon gift cards: $900
Total budget: $960
Results and Discussion
Results and Outcomes
The clinical staff member sent a study recruitment letter to the convenience sample of
435 participants from San Diego Pain Institute. A total of 183 participants responded; however,
three participants failed to answer all the items of the PMQ and thus were excluded from the
analysis, resulting in a final sample of 180 participants for a total response rate of 41.38%. The
total sample (n = 180) had a mean PMQ score of 26.56 (SD = 12.84) and a median score of
26.65. The range was 52 points, with a minimum score of 4 and a maximum score of 56 out of a
possible 104.
Data collection time frames for the participants follow:
•

No psychiatric disorder with the biopsychosocial multidisciplinary treatment group,
11/1/20 to 11/25/20 and 1/25/21 to 2/3/21

•

No psychiatric disorder without biopsychosocial multidisciplinary treatment group,
11/26/20 to 12/10/20 and 2/4/21 to 2/13/21

•

Psychiatric disorder with biopsychosocial multidisciplinary treatment group, 12/11/20
to 12/29/20 and 2/14/21 to 2/23/21

•

Psychiatric disorder without biopsychosocial multidisciplinary treatment group,
12/30/20 to 1/15/21 and 2/24/21 to 3/2/21
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The demographic details of the participants are presented in Table 1. In the no psychiatric
disorder diagnosis with biopsychosocial multidisciplinary treatment group, 42.22% were male,
57.77% were female, and their ages ranged from 25 to 65 years and over. For participants in the
no psychiatric disorder diagnosis without biopsychosocial multidisciplinary treatment group, 1%
were unknown sex, 55.55% were male, 42.22% were female, and their ages ranged from 18 to 65
years and over. For participants in the psychiatric disorder diagnosis with biopsychosocial
multidisciplinary treatment group, 2% were unknown sex, 31.11% were male, 64.44% were
female, and their ages ranged from 25 to 65 years and over. For participants in the psychiatric
disorder diagnosis without biopsychosocial multidisciplinary treatment group, 37.77% were
male, 62.22% were female, and their ages ranged from 18 to 65 years and over.
Table 1
Demographics of Study Sample
No psychiatric
disorder dx with
biopsychosocial
treatment

No psychiatric
disorder dx
without
biopsychosocial
treatment

Psychiatric
disorder dx
with
biopsychosocia
l treatment

Psychiatric
disorder dx
without
biopsychosocial
treatment

Sex

n(%)

n(%)

n(%)

n(%)

Unknown

0(0)

1(2.22)

2(4.44)

0(0)

Male

19(42.22)

25(55.55)

14(31.11)

17(37.77)

Female

26(57.77)

19(42.22)

29(64.44)

28(62.22)

18–24

0(0)

1(2.22)

0(0)

2(4.44)

25–34

1(2.22)

4(8.88)

2(4.44)

3(6.66)

Age

BIOPSYCHOSOCIAL MULTIDISCIPLINARY TREATMENT

24

35–44

11(24.44)

8(17.77)

8(17.77)

6(13.33)

45–64

16(35.55)

14(31.11)

19(42.22)

18(40)

65+

17(37.77)

18(40)

16(35.55)

16(35.55)

No High
School

0(0)

0(0)

2(4.44)

2(4.44)

High School
or GED

4(8.88)

11(24.44)

11(24.44)

13(28.88)

Some
College

15(33.33)

16(35.55)

13(28.88)

8(17.77)

Associate’s
Degree

7(15.55)

5(11.11)

8(17.77)

6(13.33)

Bachelor’s
Degree

14(31.11)

10(22.22)

11(24.44)

11(24.44)

Master’s
Degree

5(11.11)

3(6.66)

0(0)

3(6.66)

Doctorate
Degree

0(0)

0(0)

0(0)

2(4.44)

Educational
Level

Using IBM SPSS Statistics version 27 software, the data set “group” was labeled as the
independent variable and “PMQ score” as the dependent variable to explore the distribution data
of the four groups. Descriptive statistics for PMQ score were no psychiatric disorder diagnosis
with biopsychosocial multidisciplinary treatment group (M = 14.67, SD = 3.43), no psychiatric
disorder diagnosis without biopsychosocial multidisciplinary treatment (M = 15.24, SD = 4.71),
psychiatric disorder diagnosis with biopsychosocial multidisciplinary treatment (M = 34.31, SD
= 5.13), and psychiatric disorder diagnosis without biopsychosocial multidisciplinary treatment
(M = 42.02, SD = 5.38).
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A one-way between groups ANOVA was conducted to explore whether there was a
significant difference in the scores of the PMQ across the four groups. Equal variance was
assumed because the test of homogeneity was not significant (p = .06); therefore, a one-way
ANOVA was appropriate. A statistically significant difference was indicated at the p < 0.05 level
among the four groups: F (3, 176) = 381.71, p < .001, partial eta squared = .86 (Table 2). No
statistical differences were found between educational level (p = .14), age (p = .32), and sex (p
= .27).
Table 2
One-Way ANOVA Results Between Groups

Between Groups
Within Groups
Total

Sum of Squares

df

Mean Square

F

Sig

25,589.39
3,932.93
29,522.32

3
176
179

8,529.79
22.34

381.71 <.001

Post-hoc comparisons using the Tukey test indicated that the mean PMQ score for the
groups without a psychiatric disorder diagnosis demonstrated a significant difference (p < .001)
compared to the groups with a psychiatric disorder diagnosis. The mean PMQ score for the
psychiatric disorder diagnosis with biopsychosocial treatment group demonstrated a significant
difference (p < .001) compared to the psychiatric disorder diagnosis without biopsychosocial
treatment group (Table 3).
Table 3
Post-Hoc One-Way ANOVA Tests, Tukey HSD
(I)Group

(J)Group

Mean
Sig.
Difference (I-J)
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No psychiatric disorder
diagnosis with
biopsychosocial treatment

No psychiatric disorder
diagnosis without
biopsychosocial treatment

Psychiatric disorder diagnosis
with biopsychosocial
treatment

Psychiatric disorder diagnosis
without biopsychosocial
treatment

No psychiatric disorder
diagnosis without
biopsychosocial treatment
Psychiatric disorder
diagnosis with
biopsychosocial treatment
Psychiatric disorder
diagnosis without
biopsychosocial treatment
No psychiatric disorder
diagnosis with
biopsychosocial treatment
Psychiatric disorder
diagnosis with
biopsychosocial treatment
Psychiatric disorder
diagnosis without
biopsychosocial treatment
No psychiatric disorder
diagnosis with
biopsychosocial treatment
No psychiatric disorder
diagnosis without
biopsychosocial treatment
Psychiatric disorder
diagnosis without
biopsychosocial treatment
No psychiatric disorder
diagnosis with
biopsychosocial treatment
No psychiatric disorder
diagnosis without
biopsychosocial treatment
Psychiatric disorder
diagnosis with
biopsychosocial treatment

26

−.578

.93

−19.64

<.001

−27.35

<.001

.57

.93

−19.06

<.001

−26.77

<.001

19.64

<.001

19.06

<.001

−7.71

<.001

27.35

<.001

26.77

<.001

7.71

<.001

Discussion
Between the groups no psychiatric disorder diagnosis with biopsychosocial treatment and
no psychiatric disorder diagnosis without biopsychosocial treatment there was no significant
statistical difference. One possible explanation for this is that San Diego Pain Institute limits the
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opioid prescribing to a dose of 90 MME/day. It is unknown whether patients with higher daily
doses of opioids would affect the results because they may fall into a higher risk group related to
increased physiological causes, pathological issues, and disabilities.
The significant statistical difference between those in the groups with no psychiatric
disorder diagnosis and those in the groups with a psychiatric disorder diagnosis is consistent with
the findings of existing studies. A study conducted by Martel et al. (2020) found that opioid
misuse was not significantly associated with pain intensity when controlling for psychological
factors, which indicated an association between opioid misuse and psychological factors. Rogers
et al. (2019) found that anxiety sensitivity was associated with opioid misuse, severity of opioid
dependence, and number of opioids used to get high. Barry et al. (2016) found that psychiatric
comorbidities correlate with opioid use disorder and chronic pain. The study results reinforced
that those with a psychiatric disorder diagnosis are at a higher risk for opioid misuse compared to
those without a psychiatric disorder.
A significant statistical difference was found between the groups psychiatric disorder
diagnosis with biopsychosocial treatment and psychiatric disorder diagnosis without
biopsychosocial treatment. These findings suggest that participation in biopsychosocial treatment
is associated with a decreased risk of opioid misuse among adult chronic opioid-dependent
noncancer pain clinic patients with a psychiatric disorder. Traditional chronic pain management
tends to focus on the biological components with minimal emphasis on the psychological or
social components. Acknowledging the biological, psychological, and social components could
potentially affect patient outcomes. A study by Baranyi et al. (2017) found an inverse
relationship between social support and depression; it is plausible that, if the social component is
unacknowledged, it could affect the psychological component, which is a known contributing
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factor to opioid use. Incorporation of the biopsychosocial model addresses all components and
appears to have provided an alternative to opioids for pain management among those with a
psychiatric disorder.
The CDC (2016) recognizes that psychological comorbidities can interfere with pain
management and opioid tapering and patients may be prescribed benzodiazepines, leading to an
increased risk for overdose. Effective pain management relies on improved functionality,
development of coping mechanisms, and a reduced reliance on opioid medications. Research has
found that opioid medications are not an effective treatment modality for all patients, can lead to
addiction and dependency, and place patients at risk for accidental overdose (CDC, 2016).
Addressing the psychological and social components of those with a psychiatric disorder can
potentially improve pain management, decrease opioid misuse, and contribute to the national
goal of opioid reduction.
Implications for Practice
The purpose of this project was to examine the association between biopsychosocial
multidisciplinary treatment and its impact on risk of opioid medication misuse to provide
patients and providers with an alternative method for preventing opioid misuse. Prior to this
study, the clinical staff and providers at San Diego Pain Institute had limited knowledge of the
biopsychosocial model and its applicability to chronic pain patients. The minimal impact found
between the groups with no psychiatric disorder would likely not alter current practices;
however, the significant statistical difference found between the groups with a psychiatric
disorder may improve patient care. Patients with a psychiatric disorder are known to have a
higher risk of opioid misuse and overdose and are often prescribed benzodiazepines, which can
negatively interact with opioid medications (CDC, 2016). The findings of this study suggest that
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adult chronic opioid-dependent noncancer pain clinic patients with a psychiatric disorder may
reduce their risk of opioid misuse when participating in multidisciplinary biopsychosocial
treatment. Inclusion of biopsychosocial treatment for adult chronic opioid-dependent noncancer
pain clinic patients with a psychiatric disorder could potentially reduce the risk of opioid misuse,
overdose, and medication interactions and combat the national opioid crisis. A standardized
process should be implemented to educate patients with a psychiatric diagnosis and the clinical
staff and providers on the benefits of the biopsychosocial model.
Limitations for Health Policy
Currently, San Diego Pain Institute does not have collaborative partnerships with
cognitive behavioral therapists, clinical psychologists, or physical therapists. Implementing a
collaborative partnership with other clinics would require that changes be made to the policies of
the involved clinics. Each clinic would need to take a vested interest in the biopsychosocial
treatment model and its potential to decrease opioid misuse. The increased demand for effective
communication among clinics to share records and treatment plans could result in higher
administrative costs. It is feasible that clinics may consider that the costs outweigh the benefits
presented in this study.
The clinical services incorporated within the biopsychosocial treatment model may not be
attainable by all patients. Not all insurance plans provide coverage for mental health services,
which is a necessary component of the biopsychosocial treatment model. The inclusion of
coverage for mental health services on all insurance plans would require changes be made to
national and state policies. Stakeholders, such as policy makers, insurance providers, patients,
clinicians, therapists, pharmacists, and health care associations, may conclude that the findings of
this study do not warrant such changes to current policies.
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Limitations and Strengths of the Study
The use of convenience sampling in a private practice pain clinic is vulnerable to
selection bias and may not generalize to other clinics without a similar patient population. San
Diego Pain Institute does not accept Medicaid insurance and limits opioid prescribing to a dose
of 90 MME/day. Patients with Medicaid insurance and those who require higher doses of opioid
medication may have an increased complicated medical history that contributes to a higher risk
for opioid misuse. The PMQ relies on patient self-reporting, and an assumption is made that
truthful responses were provided. The study results would be altered if questions were not
understood or untruthful responses were given. While the study did account for patients with a
psychiatric disorder, it did not account for specific psychiatric disorders and how they could
affect the results. Moreover, the study does not account for other factors that may contribute to
opioid misuse, such as physical abuse, sexual abuse, or a history of high risk-taking behaviors.
Data collection time frames were affected by the COVID-19 pandemic. Data were to be obtained
over four points within a 3-month period. However, closure of the clinic to physical
appointments limited the clinical staff member’s ability to review medical records, which
resulted in an inadequate sample size and extension of the data collection to eight points over a
5-month period.
Strengths of the study include the absence of a significant difference between the
variables sex, age, and educational level, which indicates that the PMQ scores were unrelated to
the demographics. Additionally, the use of G*Power 3.1 to calculate the sample size should have
provided a sufficiently sized cohort. An adequately sized cohort should have produced clinically
relevant data.
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Suggestions for Further Research
While the present findings provide evidence that biopsychosocial treatment impacts the
risk of opioid misuse among adult chronic opioid-dependent noncancer pain clinic patients with
a psychiatric disorder, future studies are recommended to evaluate the direct correlation between
social support systems and opioid misuse. Identifying how and what types of social support
deficiencies contribute to the risk of opioid misuse could assist providers in recognizing highrisk patients, which could lead to interventions that may alter behaviors. Research should also be
considered for patients’ and providers’ perceptions of the biopsychosocial model. The lack of
collaborative partnerships with pain management clinics, cognitive behavioral therapists, clinical
psychologists, and physical therapists indicates a disconnect between the services. Understanding
patients’ and providers’ current knowledge and perceptions of the biopsychosocial model could
identify barriers to implementing collaborative partnerships. While this study did provide
clinically relevant data, they were limited in scope. A larger sample size with broader
demographics, increased daily opioid MME, and a variety of insurance plans would make the
study results more generalizable to other pain clinics. The researcher hopes that the results of this
study will contribute to opioid misuse prevention and stimulate future research to improve
chronic pain management clinical decisions.
Concluding Remarks
Differences in perception and the subjective nature of pain pose treatment challenges for
health care providers. As U.S. deaths related to opioid prescriptions increased, stricter guidelines
for opioid prescribing were adopted nationwide. These changes have led to both patients and
providers searching for alternative pain control methods. Traditional pain management has relied
on observable ailments and medication administration, rather than the biological, social, and
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psychological aspects of pain. A literature review was conducted to gain an understanding of
how the biopsychosocial model correlates with risk of opioid misuse. Engel’s (1977)
biopsychosocial model evaluates the individual’s biological, psychological, and social
components for health improvement. This model shifts our treatment options from a generalized
to an individualized plan. To identify an association between biopsychosocial multidisciplinary
treatment and its impact on risk of opioid medication misuse among adult chronic opioiddependent noncancer pain clinic patients, a quantitative retrospective four-group study design
was conducted. The results found that biopsychosocial multidisciplinary treatment reduced the
risk of opioid medication misuse among chronic pain patients with a psychiatric disorder at San
Diego Pain Institute. The researcher hopes that the results will encourage collaborative
partnerships between health services, stimulate interest in biopsychosocial multidisciplinary
treatment research, and provide an alternative method for opioid misuse prevention.
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